ROBERT M CALIFF, M.D.
Osteopathic Medicine at Erwin Rd, Durham, NC

6662114, Dec 9, 2003

Aug 21, 2000

09/642905

Robert H. Christenson - Joppa MD
Show-Hong Duh - Ellicott City MD
Robin T. Vollmer - Durham NC
E. Magnus Ohman - Durham NC
Trevor D. Thompson - Lilburn GA
L. Kristin Newby - Durham NC
Robert M. Califf - Durham NC

Duke University - Durham NC
University of Maryland - Baltimore MD

G01N 3348

702 19, 435 4, 435 15, 703 11

A method for predicting the clinical outcome for a patient after the patient has received therapy for an acute coronary syndrome such as myocardial infarction comprises: (a) optionally, but preferably, detecting a first variable comprising a serum creatine kinase-MB release curve area in the patient after initiation of said therapy; (b) detecting a second variable comprising a serum creatine kinase-MB release curve maxima in the patient after initiation of said therapy; then (c) optionally, but preferably, detecting a third variable comprising the slope of the descending portion of the serum creatine kinase-MB release curve after initiation of said therapy (wherein a steep slope for said descending portion is a more favorable indicator of clinical outcome than a shallow slope); and (d) generating a prediction of clinical outcome for said patient from the variables collected above. The method is useful in conjunction with established therapies such as thrombolytic therapy, and is particularly useful as a surrogate end point in clinical trials of new potential therapies.

5246001, Sep 21, 1993

Mar 31, 1992

7/860856

Magnus E. Ohman - Durham NC
Robert H. Christenson - Joppa MD
Robert M. Califf - Durham NC
Kristina N. Sigmon - Durham NC

Duke University - Durham NC

A61B 500

128630

The present invention is a method of diagnosing the presence of a persistent occlusion in a myocardial infarct patient undergoing thrombolytic therapy. The method comprises detecting a series of three variables from the patient and then generating the probability of the presence of a persistent occlusion from those variables. The first variable comprises a serum creatine kinase MB (CK-MB) level from a patient at the onset of thrombolytic therapy. The second variable comprises a second CK-MB level in the patient at a predetermined time after the onset of thrombolytic therapy. The third variable comprises the presence or absence of chest pain a predetermined time after the onset of thrombolytic therapy. In a preferred embodiment of the present invention, the second and third variables are detected within 30 minutes of each other and within about 1 to about 3 hours after the initial variable is detected. In an alternate embodiment a fourth variable reflecting the time from onset of chest pain to the beginning of thrombolytic therapy is included in the regression model.

6033364, Mar 7, 2000

Nov 7, 1997

8/966848

E. Magnus Ohman - Durham NC
Robert H. Christenson - Joppa MD
Robert M. Califf - Durham NC
Mary Ann O'Hanesian - Durham NC
Kristina N. Sigmon - Durham NC

Duke University - Durham NC

A61B 560

600300

The present invention is a method of diagnosing the presence of a persistent occlusion in a myocardial infarct patient undergoing thrombolytic therapy. The method comprises detecting a series of five variables from the patient and then generating the probability of the presence of a persistent occlusion from those variables. The first variable comprises a serum creatine kinase MB (CK-MB) level from a patient at the onset of thrombolytic therapy. The second variable comprises a second CK-MB level in the patient at a predetermined time after the onset of thrombolytic therapy. The third variable comprises the presence or absence of chest pain a predetermined time after the onset of thrombolytic therapy. The fourth variable comprises the serum myoglobin level in the patient at a predetermined time after the onset of thrombolytic therapy. In a preferred embodiment of the present invention, the second, third and fourth variables are detected within 30 minutes of each other and within about 1 to about 3 hours after the initial variable is detected.

2006001, Jan 19, 2006

May 16, 2003

10/514681

Robert Califf - Durham NC, US
Malcolm MacNab - Far Hills NJ, US
John MacMurray - Glasgow, GB
Marc Pfeffer - Chestnut Hills MA, US

A61P 9/10, A61K 31/00, A61K 47/00

514789000

The invention relates to a method of treating cardiovascular disease in patients following myocardial infarction comprising administering an effective amount of an ARB, especially valsartan, in combination within an effective amount of a beta-blocker to such patients.